TriangleNCT02761187 · OUTCOME
Number of Participants With Stem Cell Transplant
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline up to 5 years
Analysis population: All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis.
Groups in this outcome
1st Line of Therapy
The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
2nd Line of Therapy
The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
3rd Line of Therapy
The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
4th Line of Therapy
The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
>4th Line of Therapy
The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
| Group | Source count |
|---|---|
| 1st Line of Therapy | 1790 |
| 2nd Line of Therapy | 686 |
| 3rd Line of Therapy | 458 |
| 4th Line of Therapy | 249 |
| >4th Line of Therapy | 80 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 1st Line of Therapy | 1790 | Not reported | Not reported | Not reported | Not reported |
| 2nd Line of Therapy | 686 | Not reported | Not reported | Not reported | Not reported |
| 3rd Line of Therapy | 458 | Not reported | Not reported | Not reported | Not reported |
| 4th Line of Therapy | 249 | Not reported | Not reported | Not reported | Not reported |
| >4th Line of Therapy | 80 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1790
- group Id
- OG001
- value
- 686
- group Id
- OG002
- value
- 458
- group Id
- OG003
- value
- 249
- group Id
- OG004
- value
- 80
- denoms
- counts
- group Id
- OG000
- value
- 1790
- group Id
- OG001
- value
- 686
- group Id
- OG002
- value
- 458
- group Id
- OG003
- value
- 249
- group Id
- OG004
- value
- 80
- units
- Participants
- groups
- description
- The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG000
- title
- 1st Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG001
- title
- 2nd Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG002
- title
- 3rd Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG003
- title
- 4th Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG004
- title
- >4th Line of Therapy
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis.
- reporting Status
- POSTED
- time Frame
- Baseline up to 5 years
- title
- Number of Participants With Stem Cell Transplant
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice